West Pharmaceutical Services ($WST) CEO Michel Lagarde Receives Equity Grants
WEST PHARMACEUTICAL SERVICES INC
Subscribe to track WST
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
SEC Form 4 Filing Alert: West Pharmaceutical Services Inc ($WST) • Insider: Michel Lagarde (President and CEO, Director) • Transaction Date: September 8, 2026 • Type: Grant / Award (Code A) • Details:
- Stock Options: 37,048 total options across 3 tranches ($337.75 exercise price, exp. 2036-09-08)
- Restricted Stock Units: 14,750 total RSUs across 3 tranches • Total Units Granted: 51,798 derivative units • Cost: $0.00 • Significance: Low (Routine executive equity incentive grant)
Comprehensive Analysis
Executive Equity Grant Summary
On September 10, 2026, West Pharmaceutical Services Inc ($WST) filed a Form 4 disclosing standard annual/incentive equity awards granted to President and CEO Michel Lagarde on September 8, 2026.
Breakdown of Awards Granted:
-
Stock Options (Right to Buy):
- Tranche 1: 13,879 options (4-year annual vesting starting Sept 8, 2027)
- Tranche 2: 11,081 options (4-year annual vesting starting Sept 8, 2027)
- Tranche 3: 12,088 options (Cliff vests on Sept 8, 2031)
- Exercise Price: $337.75 per share
- Expiration Date: September 8, 2036
- Total Options: 37,048
-
Restricted Stock Units (RSUs):
- Tranche 1: 6,200 RSUs (4-year annual vesting starting Sept 8, 2027)
- Tranche 2: 4,950 RSUs (4-year annual vesting starting Sept 8, 2027)
- Tranche 3: 3,600 RSUs (Cliff vests on Sept 8, 2031)
- Total RSUs: 14,750
Trading & Market Significance
- Significance: Low. These transactions represent routine executive compensation and long-term retention grants (Code
A) at zero immediate cost to the insider, rather than open-market purchases or sales.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.